Opdivo (Nivolumab) vs Velexbru (tirabrutinib hydrochloride)

Opdivo (nivolumab) is an immunotherapy drug classified as a PD-1 inhibitor, which works by enabling the immune system to recognize and attack cancer cells, and is commonly used in the treatment of various types of cancers such as melanoma, lung cancer, and kidney cancer. Velexbru (tirabrutinib hydrochloride), on the other hand, is a Bruton's tyrosine kinase (BTK) inhibitor that interferes with the signaling that promotes cancer cell proliferation and survival, and is primarily used in the treatment of B-cell malignancies like mantle cell lymphoma. When deciding between these medications, it is crucial to consider the specific type of cancer being treated, as their mechanisms of action are suited for different cancer profiles, and a healthcare provider will recommend the most appropriate option based on the individual's diagnosis, overall health, and treatment goals.

Difference between Opdivo and Velexbru

Metric	Opdivo (Nivolumab)	Velexbru (tirabrutinib hydrochloride)
Generic name	Nivolumab	Tirabrutinib hydrochloride
Indications	Various types of cancers including melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancer	Relapsed or refractory primary central nervous system lymphoma (PCNSL)
Mechanism of action	Programmed death-1 (PD-1) immune checkpoint inhibitor that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2	Bruton's tyrosine kinase (BTK) inhibitor that irreversibly binds to BTK, preventing B-cell receptor signaling and B-cell proliferation
Brand names	Opdivo	Velexbru
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, asthenia, cough, dyspnea, decreased appetite, and others	Neutropenia, thrombocytopenia, anemia, leukopenia, rash, diarrhea, fatigue, fever, cough, and others
Contraindications	Known hypersensitivity to nivolumab or any of its excipients	Known hypersensitivity to tirabrutinib or any of its excipients
Drug class	Immune checkpoint inhibitor, monoclonal antibody	Bruton's tyrosine kinase (BTK) inhibitor
Manufacturer	Bristol-Myers Squibb	Ono Pharmaceutical Co., Ltd.

Efficacy

Opdivo (Nivolumab) Efficacy in Lymphoma

Opdivo, also known by its generic name Nivolumab, is a programmed death receptor-1 (PD-1) blocking antibody used in cancer immunotherapy. It has shown efficacy in the treatment of several types of cancer, including lymphoma. Specifically, for patients with classical Hodgkin Lymphoma (cHL) who have relapsed or refractory disease after autologous stem cell transplant (ASCT) and post-transplantation brentuximab vedotin, Nivolumab has been approved by the FDA. Clinical trials have demonstrated that Nivolumab can induce a durable response in a significant proportion of these patients, offering a new line of therapy where limited options were previously available.

Velexbru (Tirabrutinib Hydrochloride) Efficacy in Lymphoma

Velexbru, with the active ingredient tirabrutinib hydrochloride, is a Bruton's tyrosine kinase (BTK) inhibitor. It is used in the treatment of B-cell malignancies, such as certain types of non-Hodgkin lymphoma. The efficacy of Velexbru has been evaluated in clinical trials for patients with relapsed or refractory mantle cell lymphoma (MCL) and other B-cell lymphomas. The results have shown that tirabrutinib can lead to high response rates and has a favorable safety profile, making it a promising treatment option for patients with these conditions.

Comparative Efficacy in Lymphoma Treatment

When comparing the efficacy of Opdivo and Velexbru, it is important to consider the type of lymphoma and the patient's prior treatment history. Both medications have shown positive outcomes in their respective indications. Opdivo has been particularly effective for patients with cHL after failure of ASCT and other therapies, while Velexbru has been beneficial for patients with B-cell malignancies, including MCL. The choice of treatment should be individualized based on the specific clinical scenario and in consultation with a healthcare provider.

Conclusion

In conclusion, both Opdivo (Nivolumab) and Velexbru (tirabrutinib hydrochloride) have demonstrated efficacy in the treatment of different types of lymphoma. Nivolumab has become an important therapeutic option for patients with relapsed or refractory cHL, while tirabrutinib offers a new hope for those with B-cell malignancies like MCL. Ongoing research and clinical trials continue to refine the use of these drugs and expand their indications, potentially improving outcomes for patients with lymphoma.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Velexbru

Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Opdivo or Velexbru today

If Opdivo or Velexbru are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Velexbru

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: